Milacemide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Milacemide
Skeletal formula of milacemide
Names
IUPAC name
2-(Pentylamino)acetamide[1]
Identifiers
3D model (Jmol)
ChemSpider
MeSH milacemide
UNII
Properties
C7H16N2O
Molar mass 144.22 g·mol−1
log P 0.754
Related compounds
Related compounds
Tricine
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references

Milacemide (INN)[2] is an MAO-B inhibitor and glycine prodrug.[3] It has been studied for its effects on human memory and as a potential treatment for the symptoms of Alzheimer's disease.[4] Early clinical trials did not show positive results however,[3] and the drug is now abandoned.

References[edit]

  1. ^ "milacemide - Compound Summary". PubChem Compound. USA: National Center for Biotechnology Information. 8 August 2005. Identifiers and Related Records. Retrieved 9 January 2012. 
  2. ^ "International Nonproprietary Names for Pharmaceutical Substances. Supplement to WHO Chronicle, 1983, Vol. 37, No. 6 (December). Recommended International Nonproprietary Names (Rec. INN): List 23" (PDF). World Health Organization. p. 6. Retrieved 8 January 2016. 
  3. ^ a b Dysken, MW; Mendels, J; LeWitt, P; Reisberg, B; Pomara, N; Wood, J; Skare, S; Fakouhi, JD; Herting, RL (May 1992). "Milacemide: a placebo-controlled study in senile dementia of the Alzheimer type.". Journal of the American Geriatrics Society. 40 (5): 503–6. PMID 1634705. 
  4. ^ Harris, Carol Turkington ; foreword by Joseph R. (2002). The encyclopedia of the brain and brain disorders (2nd ed.). New York, NY: Facts on File. ISBN 0-8160-4774-X.